BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cidon EU, Centeno RG, Lagarto EG, Peral JI. HER-2 Evaluation in a Specific Gastric Cancer Population with the Highest Rate of Mortality in Spain. J Oncol. 2011;2011:391564. [PMID: 22131990 DOI: 10.1155/2011/391564] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Pyo JS, Sohn JH, Kim WH. Concordance rate between HER2 immunohistochemistry and in situ hybridization in gastric carcinoma: systematic review and meta-analysis. Int J Biol Markers. 2016;31:e1-10. [PMID: 26349670 DOI: 10.5301/jbm.5000171] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
2 Cidon EU, Ellis SG, Inam Y, Adeleke S, Zarif S, Geldart T. Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. Cancers (Basel). 2013;5:64-91. [PMID: 24216699 DOI: 10.3390/cancers5010064] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
3 Raj N, Verma D, Kumar A, Rai P, Rao RN. HER2 Oncogene Amplification and Immunohistochemical Profiling in Gastric Adenocarcinoma. Discoveries (Craiova) 2018;6:e83. [PMID: 32309603 DOI: 10.15190/d.2018.6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Li DM, Zhang J, Li WM, Cui JT, Pan YM, Liu SQ, Xing R, Lu YY. MAWBP and MAWD inhibit proliferation and invasion in gastric cancer. World J Gastroenterol 2013; 19(18): 2781-2792 [PMID: 23687415 DOI: 10.3748/wjg.v19.i18.2781] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
5 Vita FD, Martino ND, Fabozzi A, Laterza MM, Ventriglia J, Savastano B, Petrillo A, Gambardella V, Sforza V, Marano L, Auricchio A, Galizia G, Ciardiello F, Orditura M. Clinical management of advanced gastric cancer: The role of new molecular drugs. World J Gastroenterol 2014; 20(40): 14537-14558 [PMID: 25356019 DOI: 10.3748/wjg.v20.i40.14537] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
6 Gu J, Zheng L, Wang Y, Zhu M, Wang Q, Li X. Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis. Tumour Biol. 2014;35:5315-5321. [PMID: 24557541 DOI: 10.1007/s13277-014-1693-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
7 Roviello G, Polom K, Petrioli R, Marano L, Marrelli D, Paganini G, Savelli V, Generali D, De Franco L, Ravelli A, Roviello F. Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. Tumour Biol 2016;37:127-40. [PMID: 26566626 DOI: 10.1007/s13277-015-4408-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
8 Kulig J, Kołodziejczyk P, Kulig P, Legutko J. Targeted therapy for gastric cancer--current status. J Oncol Pharm Pract 2013;19:75-81. [PMID: 22711713 DOI: 10.1177/1078155212449030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
9 Lei YY, Huang JY, Zhao QR, Jiang N, Xu HM, Wang ZN, Li HQ, Zhang SB, Sun Z. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. World J Surg Oncol 2017;15:68. [PMID: 28327158 DOI: 10.1186/s12957-017-1132-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]